Table 1 Participant demographics at baseline (14 days after second SARS-CoV-2 vaccination)
Breakthrough infection during follow-up | Variant | ||||
|---|---|---|---|---|---|
Total (N = 6076) | No (N = 5572) | Yes (N = 504) | Delta (N = 127) | Omicron (N = 364) | |
Age at enrolment (median, IQR) | 64 (54, 75) | 64 (55, 75) | 56 (47, 68) | 58 (48, 69) | 55 (46, 68) |
Age Group (N, %) | |||||
<55 | 1615 (26.6) | 1380 (24.8) | 235 (46.6) | 51 (40.2) | 177 (48.6) |
55–64 | 1543 (25.4) | 1425 (25.6) | 118 (23.4) | 34 (26.8) | 79 (21.7) |
≥65 | 2918 (48.0) | 2767 (49.7) | 151 (30.0) | 42 (33.1) | 108 (29.7) |
Sex (N, %) | |||||
Male | 2675 (44.0) | 2474 (44.4) | 201 (39.9) | 62 (48.8) | 132 (36.3) |
Female | 3401 (56.0) | 3098 (55.6) | 303 (60.1) | 65 (51.2) | 232 (63.7) |
Vaccine type (N, %) | |||||
Pfizer-BioNTech | 3369 (55.4) | 3113 (55.9) | 256 (50.8) | 72 (56.7) | 179 (49.2) |
Moderna | 2363 (38.9) | 2168 (38.9) | 195 (38.7) | 54 (42.5) | 135 (37.1) |
AstraZeneca/mRNA | 344 (5.7) | 291 (5.2) | 53 (10.5) | 1 (0.8) | 50 (13.7) |
Population group (N, %) | |||||
Individuals at increased riska | 1434 (23.6) | 1322 (23.7) | 112 (22.2) | 28 (22.0) | 83 (22.8) |
Healthcare worker | 432 (7.1) | 371 (6.7) | 61 (12.1) | 2 (1.6) | 55 (15.1) |
General population | 4210 (69.3) | 3879 (69.6) | 331 (65.7) | 97 (76.4) | 226 (62.1) |
